Eli Lilly Buys Psychedelic Drug Developer AtaiBeckley for $2.8 Billion to Advance Depression Treatment
Eli Lilly agreed to buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, offering $6.75 per share in cash and a contingent value right worth up to $2.50 per share tied to clinical milestones.
The acquisition expands Eli Lilly’s neuroscience portfolio, providing access to BPL-003, an intranasal psychedelic therapy in Phase 3 trials for treatment-resistant depression. The deal values AtaiBeckley at roughly a 40% premium to recent trading averages and is expected to close in the third quarter of 2026, subject to regulatory approvals.
From the sources (11 posts)
@zerohedge*LILLY SAID TO NEAR DEAL FOR PSYCHEDELIC DRUGMAKER ATAIBECKLEY
@stockmktnewzEli Lilly $LLY is reportedly in talks to acquire medical psychedelic company AtaiBeckley - Bloomberg
@wallstengineEli Lilly $LLY agreed to acquire AtaiBeckley $ATAI for up to $3.8B. Terms: $6.75/share cash upfront, valuing AtaiBeckley at about $2.8B, plus a CVR worth up to $2.50/share tied to BPL-003 and VLS-01 milestones. The upfront price is a roug
@cnbcEli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
@firstsquawkLILLY TO ACQUIRE ATAIBECKLEY TO ADVANCE THERAPIES FOR TREATMENT-RESISTANT DEPRESSION AND OTHER MENTAL HEALTH CONDITIONS || TO PAY $6.75 PER SHARE CASH PLUS UP TO $2.5 PER SHARE IN CVR || DEAL VALUED AT $2.8 BLN UPFRONT WITH UP TO $1 BLN IN
@polymarketJUST IN: Eli Lilly agrees to acquire Thiel-backed psychedelic drug developer AtaiBeckley.
@yahoofinanceEli Lilly is expanding heavily into neuroscience with a deal valued at $2.8 billion upfront to acquire AtaiBeckley. The deal could reach up to $3.8 billion if milestones are met.
@reutersAtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
@businessThe deal deepens Lilly’s longstanding presence in neuroscience drugs
@reutersAtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
@elilillyandcoEmerging research could offer a new approach to treatment-resistant depression. Read more on our agreement to acquire AtaiBeckley, a clinical-stage company developing innovative medicines for mental health conditions.